Galderma Group (GALD) Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GALD from our risk checks.
GALD Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 161.50 |
| 52 Week High | CHF 171.90 |
| 52 Week Low | CHF 107.40 |
| Beta | -0.058 |
| 1 Month Change | -1.46% |
| 3 Month Change | 4.46% |
| 1 Year Change | 39.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 152.34% |
Recent News & Updates
Narrative Update • Jun 03
GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk
Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.Narrative Update • May 13
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Concentration Risk
Analysts have nudged their average price target for Galderma higher by around CHF 5 to reflect updated assumptions for revenue growth, profit margins and longer term P/E expectations, following a series of recent target increases from firms such as Morgan Stanley, Citi, RBC Capital, Berenberg, H.C. Wainwright and Barclays. Analyst Commentary Recent research on Galderma Group has been active, with several firms updating their views and price targets.
Narrative Update • Apr 28
GALD: Higher Fair Value View Will Support Future Re Rating Conviction
Analysts have increased the Galderma Group fair value estimate by about CHF 48, from roughly CHF 192 to around CHF 240. They cite recent price target increases across several firms, along with support from product driven growth assumptions and a higher future P/E multiple.Recent updates
Narrative Update • Jun 03
GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk
Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.Narrative Update • May 13
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Concentration Risk
Analysts have nudged their average price target for Galderma higher by around CHF 5 to reflect updated assumptions for revenue growth, profit margins and longer term P/E expectations, following a series of recent target increases from firms such as Morgan Stanley, Citi, RBC Capital, Berenberg, H.C. Wainwright and Barclays. Analyst Commentary Recent research on Galderma Group has been active, with several firms updating their views and price targets.Narrative Update • Apr 28
GALD: Higher Fair Value View Will Support Future Re Rating Conviction
Analysts have increased the Galderma Group fair value estimate by about CHF 48, from roughly CHF 192 to around CHF 240. They cite recent price target increases across several firms, along with support from product driven growth assumptions and a higher future P/E multiple.
Narrative Update • Apr 14
GALD: Elevated Expectations For Dermatology Franchise Will Likely Cap Future Share Upside
Analysts have raised the Galderma Group price target by CHF 7 to reflect updated expectations for revenue growth, profit margin and future P/E, supported by a series of recent CHF-based target increases from several research houses. Analyst Commentary Recent research updates show a cluster of higher CHF based price targets for Galderma Group, with several firms revising their assumptions around growth, margins and P/E multiples.Narrative Update • Mar 31
GALD: Rising Optimism Will Meet Pediatric Skin Franchise Execution Risk
The updated analyst price target for Galderma Group moves higher to reflect Street research that cites support from products like Nemluvio, tighter profit margin assumptions, a slightly adjusted discount rate, and a modestly lower future P/E expectation across recent CHF 155 to CHF 260 target revisions. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into a CHF 155 to CHF 260 range, which signals higher conviction in Galderma Group's valuation support at current levels.Narrative Update • Mar 17
GALD: High Expectations For Key Therapies Will Likely Restrain Future Share Returns
Narrative Update on Galderma Group The updated analyst price target for Galderma Group has moved higher in the latest model, aligning with recent Street target increases to CHF 155, CHF 200 and CHF 260, as analysts highlight support from products such as Nemluvio and adjustments to growth and margin assumptions. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets in the CHF 155 to CHF 260 range, with different attitudes on how much upside may be left.Narrative Update • Mar 03
GALD: Elevated Growth Assumptions Will Likely Pressure Shares Despite Raised Outlook
Analysts have raised their Galderma Group price target to CHF 195 from CHF 155, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E that modestly reduce estimated fair value to CHF 110.71 from CHF 111.24. Analyst Commentary The latest price target move to CHF 195 sits well above the estimated fair value of CHF 110.71, which signals that some analysts are embedding optimistic assumptions on growth and profitability.Narrative Update • Feb 16
GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction
Analysts have raised their price target on Galderma Group to CHF 195 from CHF 155, reflecting updated views on revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent research points to a more constructive stance on Galderma Group, with bullish analysts lifting their price targets and expressing increased confidence in the company’s execution and valuation framework.Narrative Update • Feb 02
GALD: Higher Future P/E Assumptions Will Likely Pressure Shares Forward
Analysts have lifted their price target on Galderma Group to CHF 195 from CHF 155, citing updated assumptions that include higher fair value estimates, a slightly adjusted discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. Analyst Commentary The move to a CHF 195 price target is framed around updated valuation work, with higher assumed fair value, a revised discount rate, and adjusted revenue and margin assumptions.Narrative Update • Jan 19
GALD: Raised Growth Outlook And L’Oréal Stake Increase Will Support Re Rating
Analysts have raised their blended price target range for Galderma Group to approximately CHF 195 to CHF 200 from about CHF 140 to CHF 165, citing updated fair value estimates, revised assumptions for revenue growth and profit margins, as well as a higher projected P/E multiple. Analyst Commentary Recent Street research points to a more constructive stance on Galderma Group, with several bullish analysts lifting their price targets into the CHF 140 to CHF 195 range.Narrative Update • Jan 05
GALD: Rising Market Optimism Will Meet Execution Risk And Fairly Balanced Prospects
Analysts have made a marginal trim to their fair value estimate for Galderma Group to approximately CHF 159.55 per share, even as Street price targets have moved higher into a CHF 140 to CHF 182 range. This reflects updated views on the stock's P/E assumptions and recent research from multiple banks.Narrative Update • Dec 14
GALD: Rising Market Optimism Will Meet Execution And Competitive Challenges Ahead
Analysts have nudged their blended price target for Galderma Group higher by approximately CHF 6, reflecting increased confidence in the companys faster than previously expected revenue growth, improving profit margins, and a slightly richer forward price-to-earnings multiple supported by a series of recent target hikes across the Street. Analyst Commentary Recent target hikes from multiple firms underscore a constructive stance on Galderma Group’s medium term outlook, with bullish analysts pointing to accelerating top line momentum and improving profitability as key drivers of upside to current valuation.Narrative Update • Nov 30
GALD: Upward Momentum In Pricing Will Face Competitive And Execution Risks Ahead
Galderma Group's fair value estimate has been raised from CHF 150.37 to CHF 153.80. This reflects analysts' positive outlook supported by a series of recent upward price target revisions in light of expectations of continued revenue growth and stable profitability.Narrative Update • Nov 16
GALD: Momentum In Product Approvals And Expansion Will Face Execution Challenges
Galderma Group’s analyst price target has been revised upward from CHF 149.91 to CHF 150.37. This reflects positive analyst sentiment, driven by higher recent target increases and confidence in the company’s growth prospects.Narrative Update • Oct 31
GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside
The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.Analysis Article • Oct 29
Is Galderma Group AG (VTX:GALD) Trading At A 40% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Galderma Group fair value estimate is CHF239 Current share...Narrative Update • Oct 17
Global Aesthetics And Aging Trends Will Drive Expansion
The analyst price target for Galderma Group has been raised, with new estimates increasing from CHF 140.69 to CHF 142.41. This change reflects analysts' optimism on the company's outlook amid steady growth expectations and supportive recent research updates.Narrative Update • Aug 27
Global Aesthetics And Aging Trends Will Drive Expansion
Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.Analysis Article • Aug 24
Is Galderma Group (VTX:GALD) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Narrative • May 12
Nemluvio Launch And Global Expansion Will Shape Therapeutic Dermatology Markets
Launch of Nemluvio and international expansion in China and India are expected to significantly boost revenue growth and market share.Shareholder Returns
| GALD | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -1.5% | 2.7% | 0.4% |
| 1Y | 39.3% | 23.8% | 6.6% |
Return vs Industry: GALD exceeded the Swiss Pharmaceuticals industry which returned 23.8% over the past year.
Return vs Market: GALD exceeded the Swiss Market which returned 6.6% over the past year.
Price Volatility
| GALD volatility | |
|---|---|
| GALD Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: GALD has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: GALD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 7,676 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| GALD fundamental statistics | |
|---|---|
| Market cap | CHF 37.88b |
| Earnings (TTM) | CHF 487.98m |
| Revenue (TTM) | CHF 4.17b |
77.6x
P/E Ratio9.1x
P/S RatioIs GALD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALD income statement (TTM) | |
|---|---|
| Revenue | US$5.24b |
| Cost of Revenue | US$1.63b |
| Gross Profit | US$3.61b |
| Other Expenses | US$3.00b |
| Earnings | US$613.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 2.61 |
| Gross Margin | 68.86% |
| Net Profit Margin | 11.70% |
| Debt/Equity Ratio | 32.0% |
How did GALD perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield17%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 11:27 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galderma Group AG is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yihan Li | Barclays |
| James Gordon | Barclays |
| Fulvio Cazzol | Berenberg |